On March 26th, the US FDA granted approval for Merck’s WINREVAIR™ (sotatercept-csrk), marking a significant milestone in pulmonary arterial hypertension (PAH) treatment. PAH, characterized by elevated blood pressure in the arteries connecting the heart and lungs, poses a grave risk of heart failure.
An ActRIIA fusion protein got FDA approved for PAH treatment
- Post author:
- Post published:March 28, 2024
- Post category:uncategorized